UTI Recurrence Drug Linked to Lysosomal Function by EPFL Researchers

Researchers at EPFL's Laboratory of Microbiology and Microtechnology have uncovered the molecular mechanism of a drug used to treat urinary tract infection (UTI) recurrence. This drug has been approved in Switzerland for over a certain period, and the findings link its function to lysosomal activity.

Originally published by gnews